Allysta Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12819 SE 38th St, Bellevue, Washington, ...Website
www.allysta.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Allysta Pharmaceuticals
Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical company focused on developing innovative medicines for rare diseases with high unmet needs. The company specializes in therapeutic peptides that exhibit multiple biological actions, including anti-fibrotic and anti-inflammatory effects. Their lead drug, ALY688, is the first adiponectin receptor agonist to enter human testing, targeting Duchenne muscular dystrophy and showing potential benefits in various inflammatory and fibrotic conditions. Allysta is committed to building breakthrough therapies on a strong scientific foundation to improve patient outcomes.Explore more
Popular SearchesALLYSTA PHARMACEUTICALS IncAllystaSIC Code 28,283NAICS Code 32,325Show moreAllysta Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Allysta Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Allysta Pharmaceuticals recently announced quarterly report
Allysta Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Allysta Pharmaceuticals launches new products
Click to see if Allysta Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Allysta Pharmaceuticals
Check out if Allysta Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Allysta Pharmaceuticals has new funding data
Check if Allysta Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Allysta Pharmaceuticals
Compare insights from companies similar to Allysta Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Allysta Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Allysta Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Allysta Pharmaceuticals.
Allysta Pharmaceuticals financials insights
Gather financial insights about Allysta Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$5M
Allysta Pharmaceuticals Tech Stack
A closer look at the technologies used by Allysta Pharmaceuticals
Allysta Pharmaceuticals News & Media
Allysta Pharmaceuticals, Inc. to Present at OIS@ASCRS
SAN MATEO, CA / ACCESSWIRE / April 25, 2019 / Allysta Pharmaceuticals, Inc. (Allysta) today announced that Henry Hsu, M.D., the company's Chief Executive Officer and President, will present at OIS@ASCRS on May 2, 2019, in San Diego, California. Dr. Hsu will present an overview of the development program for its novel, first-in-class peptide therapeutic in a morning breakout session focused on new drugs being developed for dry eye disease. About OIS The Ophthalmology InnovationAllysta Pharmaceuticals, Inc. to Present New Results on ALY688 at the Annual Meeting of ARVO
SAN MATEO, CA / ACCESSWIRE / April 22, 2019 / Allysta Pharmaceuticals, Inc. (Allysta) today announced that Kathryn Crawford, Ph.D., the company's Vice President and Head of Non-Clinical Development, will present at the Annual Meeting of ARVO, in Vancouver, British Columbia. Dr. Crawford will present new data on the effects of ALY688, an adiponectin analogue, in a rabbit model of dry eye disease. In a session covering dry eye disease on Sunday April 28, 8:00
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Allysta Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical company focused on developing innovative medicines for rare diseases with high unmet needs. The company specializes in therapeutic peptides that exhibit multiple biological actions, including anti-fibrotic and anti-inflammatory effects. Their lead drug, ALY688, is... Read More
